Knee Osteoarthritis Drugs Market Size, Share and Forecast 2034
Knee Osteoarthritis Drugs Market Growth, Size, Trends Analysis - By Drug Type, By Route of Administration, By Age Group - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Oct-2025 | Report ID: HLCA25315 | Pages: 1 - 258 | Formats*: |
| Category : Healthcare | |||
Knee Osteoarthritis Drugs Market Introduction and Overview
According to SPER Market Research, the Global Knee Osteoarthritis Drugs Market is estimated to reach USD 15.3 billion by 2034 with a CAGR of 8.24%.
The report includes an in-depth analysis of the Global Knee Osteoarthritis Drugs Market, including market size and trends, product mix, Applications, and supplier analysis. The global Knee Osteoarthritis Drugs Market was valued at USD 6.93 billion in 2024, and it is expected to rise at a 8.24% CAGR from 2025 to 2034. The rising incidence of osteoarthritis, especially in the elderly, is driving the global market for knee osteoarthritis medications. The market is growing as a result of advancements in drug development, growing awareness of available treatments, and consumer demand for better joint function and efficient pain relief. These factors encourage the use of both prescription and over-the-counter medications.
By Drug Type Insights:
The widespread use of NSAIDs as the first-line treatment for pain and inflammation was the reason for their prominence. Because NSAIDs are more affordable, more widely available, and more effective than other prescription medications, ibuprofen, naproxen, and celecoxib are frequently prescribed. Additionally, the product improvement in mobility and pain relief, as well as continuous development for safer and more effective formulations like topical and COX-2 selective inhibitors, are responsible for their strong market position.
By Route of Administration Insights:
In 2024, the parenteral segment held the largest market share. When compared to oral and topical medications, the parenteral segment's superior bioavailability, longer duration of pain relief, and quick onset of action have strengthened its market dominance. When oral therapy options are insufficient for treating moderate to severe OA, this category also includes injectable corticosteroids, viscosupplementation (HA injections), and different biologics. The growing popularity of long-acting injectables and minimally invasive procedures also contributed to the segment's growth.
By Age Group Insights:
The over-65 market segment is anticipated to maintain its leading position. As people age, their joints become less flexible, inflammation increases, and cartilage degeneration causes pain. These factors have led to an increase in the prevalence of OA, including knee OA. The need for knee OA medications has therefore been further fueled by the growing elderly population, longer life expectancy, and increased awareness of available treatments.
Regional Insights:
North America leads the world market for knee osteoarthritis medications because of its high rate of osteoarthritis, developed healthcare system, and substantial healthcare expenditures. Market expansion is driven by extensive prescription and over-the-counter medication availability, advanced research and development, and high patient and healthcare provider awareness. Leading pharmaceutical companies, extensive insurance coverage, and the early adoption of cutting-edge treatments all contribute to North America's standing as the world's largest regional supplier of knee osteoarthritis medications.
Market Competitive Landscape:
The primary pharmaceutical companies that concentrate on the research, development, and commercialization of advanced therapies dominate the fiercely competitive global market for knee osteoarthritis medications. Product innovation, mergers and acquisitions, strategic alliances, and entry into emerging markets are important tactics. Targeting both the prescription and over-the-counter markets, companies compete on the basis of drug efficacy, safety, and delivery methods.
Recent Developments:
In November 2024, the U.S. Food and Drug Administration (FDA) granted Genascence Corporation fast-track designation for GNSC-001, a potential first-in-class gene therapy for osteoarthritis in the knee. This approval represented a breakthrough in knee OA treatment options, addressing the unmet need for OA, a common and crippling disease.
In September 2025, Novo Nordisk is investigating treating osteoarthritis in the knees with its obesity medications, such as Wegovy. To address the comorbidities associated with obesity, clinical trials are being conducted to evaluate the effectiveness of semaglutide-based therapies in managing osteoarthritis symptoms.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Drug Type, By Route of Administration, By Age Group |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Anika Therapeutics, Avanos, Biotech Healthcare, Bioventus, Ferring Pharmaceuticals, Fidia Pharma, GlaxoSmithKline (GSK), Haleon, Kenvue, Organon LLC, Pacira Pharmaceuticals, Pfizer, Premier Surgical, Sanofi, Stellar Pharmaceuticals. |
- Global Knee Osteoarthritis Drugs Market Size (FY 2021-FY 2034)
- Overview of Global Knee Osteoarthritis Drugs Market
- Segmentation of Global Knee Osteoarthritis Drugs Market By Drug Type (Non-steroidal anti-inflammatory drugs, Corticosteroids, Viscosupplementation, Analgesics, Other drug types)
- Segmentation of Global Knee Osteoarthritis Drugs Market By Route of Administration (Oral, Parenteral, Topical)
- Segmentation of Global Knee Osteoarthritis Drugs Market By Age Group (18 – 44,45 –-64, Above 65)
- Statistical Snap of Global Knee Osteoarthritis Drugs Market
- Expansion Analysis of Global Knee Osteoarthritis Drugs Market
- Problems and Obstacles in Global Knee Osteoarthritis Drugs Market
- Competitive Landscape in the Global Knee Osteoarthritis Drugs Market
- Details on Current Investment in Global Knee Osteoarthritis Drugs Market
- Competitive Analysis of Global Knee Osteoarthritis Drugs Market
- Prominent Players in the Global Knee Osteoarthritis Drugs Market
- SWOT Analysis of Global Knee Osteoarthritis Drugs Market
- Global Knee Osteoarthritis Drugs Market Future Outlook and Projections (FY 2025-FY 2034)
- Recommendations from Analyst
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
6. Competitive Landscape
- 6.1. Global Knee Osteoarthritis Drugs Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Knee Osteoarthritis Drugs Market
7. Global Knee Osteoarthritis Drugs Market, By Drug Type (USD Million) 2021-2034
- 7.1. Non-steroidal anti-inflammatory drugs (NSAIDs)
- 7.2. Corticosteroids
- 7.3. Viscosupplementation
- 7.4. Analgesics
- 7.5. Other drug types
8. Global Knee Osteoarthritis Drugs Market, By Route of Administration (USD Million) 2021-2034
- 8.1. Oral
- 8.2. Parenteral
- 8.3. Topical
9. Global Knee Osteoarthritis Drugs Market, By Age Group (USD Million) 2021-2034
- 9.1. 18 - 44
- 9.2. 45 - 64
- 9.3. Above 65
10. Global Knee Osteoarthritis Drugs Market, (USD Million) 2021-2034
- 10.1. Global Knee Osteoarthritis Drugs Market Size and Market Share
11. Global Knee Osteoarthritis Drugs Market, By Region, (USD Million) 2021-2034
- 11.1. Asia-Pacific
- 11.1.1. Australia
- 11.1.2. China
- 11.1.3. India
- 11.1.4. Japan
- 11.1.5. South Korea
- 11.1.6. Rest of Asia-Pacific
- 11.2. Europe
- 11.2.1. France
- 11.2.2. Germany
- 11.2.3. Italy
- 11.2.4. Spain
- 11.2.5. United Kingdom
- 11.2.6. Rest of Europe
- 11.3. Middle East and Africa
- 11.3.1. Kingdom of Saudi Arabia
- 11.3.2. United Arab Emirates
- 11.3.3. Qatar
- 11.3.4. South Africa
- 11.3.5. Egypt
- 11.3.6. Morocco
- 11.3.7. Nigeria
- 11.3.8. Rest of Middle-East and Africa
- 11.4. North America
- 11.4.1. Canada
- 11.4.2. Mexico
- 11.4.3. United States
- 11.5. Latin America
- 11.5.1. Argentina
- 11.5.2. Brazil
- 11.5.3. Rest of Latin America
12. Company Profile
- 12.1. Anika Therapeutics
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
- 12.2. Avanos
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
- 12.3. Biotech Healthcare
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
- 12.4. Bioventus
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
- 12.5. Ferring Pharmaceuticals
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
- 12.6. Fidia Pharma
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
- 12.7. GlaxoSmithKline
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
- 12.8. Haleon
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
- 12.9. Kenvue
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
- 12.10. Organon LLC
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
- 12.11. Pacira Pharmaceuticals
- 12.11.1. Company details
- 12.11.2. Financial outlook
- 12.11.3. Product summary
- 12.11.4. Recent developments
- 12.12. Pfizer
- 12.12.1. Company details
- 12.12.2. Financial outlook
- 12.12.3. Product summary
- 12.12.4. Recent developments
- 12.13. Premier Surgical
- 12.13.1. Company details
- 12.13.2. Financial outlook
- 12.13.3. Product summary
- 12.13.4. Recent developments
- 12.14. Sanofi
- 12.14.1. Company details
- 12.14.2. Financial outlook
- 12.14.3. Product summary
- 12.14.4. Recent developments
- 12.15. Stellar Pharmaceuticals
- 12.15.1. Company details
- 12.15.2. Financial outlook
- 12.15.3. Product summary
- 12.15.4. Recent developments
- 12.16. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Knee Osteoarthritis Drugs Market is projected to reach USD 15.3 billion by 2034, growing at a CAGR of of 8.24% during the forecast period.
Knee Osteoarthritis Drugs Market grew in Market size from 2025. The Market is expected to reach USD 15.3 billion by 2034, at a CAGR of 15.3 billion% during the forecast period.
Knee Osteoarthritis Drugs Market CAGR of 8.24% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Knee Osteoarthritis Drugs Market size is USD 15.3 billion from 2025 to 2034.
Knee Osteoarthritis Drugs Market is covered By Drug Type, By Route of Administration, By Age Group
The North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa is the highest Market share in the Knee Osteoarthritis Drugs Market.
Anika Therapeutics, Avanos, Biotech Healthcare, Bioventus, Ferring Pharmaceuticals, Fidia Pharma, GlaxoSmithKline (GSK), Haleon, Kenvue, Organon LLC, Pacira Pharmaceuticals, Pfizer, Premier Surgical, Sanofi, Stellar Pharmaceuticals.
The report includes an in-depth analysis of the Global Knee Osteoarthritis Drugs Market, including market size and trends, product mix, Applications, and supplier analysis.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
